Cybin Inc. Acquires Small Pharma Inc.

Revive Therapeutics Agrees to Acquire Psilocin Pharma Corp.

February 11, 2020

Pharmaceuticals

Revive Therapeutics Ltd. entered into a letter of intent to acquire all issued and outstanding securities of Psilocin Pharma Corp. for an aggregate purchase price of $2.75 million to be satisfied by issuing 55 million common shares of Revive (deemed $0.05/share). Revive deposited 10 million shares ($500,000) into escrow as a deposit; the closing is subject to due diligence and execution of a definitive share exchange agreement.

Blue Water Ventures International Acquires Psycheceutical, Inc.

January 20, 2022

Biotechnology

Blue Water Ventures International, Inc. (BWVI) has completed a merger to acquire Psycheceutical, Inc., making the biotech a wholly-owned subsidiary. BWVI — a publicly-listed company — will pivot its business to focus on psychedelic drug development and intends to provide near-term capital as Psycheceutical advances its delivery technologies toward initial clinical trials.

Blackhawk Growth Corp Acquires Trip Pharma Inc.

October 13, 2020

Healthcare Services

Blackhawk Growth Corp. completed the acquisition of all outstanding shares of Trip Pharma Inc., an Edmonton-based psychedelic development and wellness company led by Dr. Krista Leicht. The transaction was satisfied largely with issuance of common shares to Trip Pharma shareholders and brings Trip Pharma into Blackhawk's existing healthcare/cannabis investment portfolio as it pursues clinical research and a psychiatric research clinic focused on psilocybin-based therapies.

Big Cypress Acquisition Corp. Completes Business Combination with SAB Biotherapeutics

October 20, 2021

Biotechnology

Big Cypress Acquisition Corp., a Nasdaq-listed special purpose acquisition company, received shareholder approval to complete a business combination with clinical-stage biopharmaceutical company SAB Biotherapeutics. Upon closing, the combined company will be named SAB Biotherapeutics, Inc. and its common stock and warrants are expected to trade on Nasdaq, providing SAB with public-market capital to advance its antibody immunotherapy platform and clinical programs.

Otsuka Pharmaceutical Acquires Mindset Pharma

August 31, 2023

Biotechnology

Otsuka Pharmaceutical Co., Ltd., through its wholly owned U.S. subsidiary Otsuka America, Inc., agreed to acquire Mindset Pharma Inc. in an all-cash statutory plan of arrangement valued at approximately CAD 80 million. The acquisition adds Mindset’s next-generation psychedelic and non-psychedelic drug discovery assets and synthesis capabilities to Otsuka’s psychiatry and neurology pipeline.

Shionogi Inc. Acquires Qpex Biopharma, Inc.

June 26, 2023

Pharmaceuticals

Shionogi Inc., the U.S. subsidiary of Shionogi & Co., Ltd., entered into a definitive agreement to acquire San Diego-based clinical-stage antimicrobial developer Qpex Biopharma, Inc. The acquisition (upfront $100 million plus up to $40 million in milestones) brings Qpex's investigational beta-lactamase inhibitor xeruborbactam and expands Shionogi's infectious disease R&D capabilities and pipeline.